Sildenafil: two decades of benefits or risks?

References

• NIH Consensus Conference. NIH Consensus Development Panel on Impotence. J Am Med Assoc 1993;270:83–90
   PubMed Web of Science ®Google Scholar
• Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU iIternational 1999;84:50–6
   PubMed Web of Science ®Google Scholar
• Kendirci M, Nowfar S, Hellstrom WJG, Orleans N. The impact of vascular risk factors on erectile function. Drugs of Today 2005;41:65–74
   PubMedGoogle Scholar
• Katzenstein L. Viagra – The remarkable story of the discovery and launch. New York: CMD Publishing; 2001
   Google Scholar
• Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. International journal of impotence research 2002;14:466–71
   PubMed Web of Science ®Google Scholar
• Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinology and Metabolism Clinics of North America 2007;36:453–63
   PubMedGoogle Scholar
• Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New Engl J Med 1996;334:873–7
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Hellstrom W, Kaiser F, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl J Med 1997;336:1–7
   PubMed Web of Science ®Google Scholar
• Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31:799–808
   PubMed Web of Science ®Google Scholar
• Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafill citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53:61S–5S
   PubMed Web of Science ®Google Scholar
• Montorsi F, Padma-nathan H, Buvat J. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004;1:168–78
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Stecher V, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003;62:400–3
   PubMed Web of Science ®Google Scholar
• Sáenz de Tejada I. Vardenafil duration of action. European urology 2006;50:901–2
   Google Scholar
• Shabsigh R, Burnett AL, Eardley I, et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU International 2005;96:857–63
   PubMed Web of Science ®Google Scholar
• Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257–61
   PubMedGoogle Scholar
• Campbell SF. Science, art and drug discovery: a personal perspective. Clinical Science 2000 Oct;99:255–60
   PubMed Web of Science ®Google Scholar
• Palumbo F, Bettocchi C, Selvaggi FP, et al. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001;40:176–80
   PubMed Web of Science ®Google Scholar
• Eardley I, Morgan R, Dinsmore W, et al. Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiatry 2001 Apr;178:325–30
   PubMedGoogle Scholar
• Meuleman E, Cuzin B, Opsomer RJ, et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU International 2001;87:75–81
   PubMed Web of Science ®Google Scholar
• Montorsi F, Dermott TEDMC, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011–18
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397–404
   PubMed Web of Science ®Google Scholar
• Christiansen E, Guirguis WR, Cox D, Osterloh IH. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000 Jun;12:177–82
   PubMed Web of Science ®Google Scholar
• Benchekroun A, Faik M, Benjelloun S, et al. A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. Int J Impot Res 2003;15:S19–24
   Google Scholar
• Fujisawa M, Sawada K. Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. Archives of Andrology 2004;50:255–60
   PubMed Web of Science ®Google Scholar
• Levinson IP, Khalaf IM, Shaeer KZM, Smart DO. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003;15:S25–9
   Google Scholar
• Gómez F, Davila H, Costa A, et al. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002;14:S42–7
   PubMedGoogle Scholar
• Becher E, Tejada Noriega A, Gomez R, Decia R. Sildenafil citrate (Viagra 1) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, flexible-dose escalation study. Int J Impot Res. 2002;S2:S33–41
   Google Scholar
• Lim PHC, Ng FC, Cheng CWS, et al. Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: pre-marketing experience (ASSESS-I evaluation). The Journal of international medical research 2002;30:137–43
   PubMedGoogle Scholar
• Tan HM, Moh CLC, Mendoza JB, et al. Asian sildenafil efficacy and safety study (assess-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000;56:635–40
   PubMed Web of Science ®Google Scholar
• Chen KK, Hsieh JT, Huang ST, et al. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. International journal of impotence research 2001;13:221–9
   PubMed Web of Science ®Google Scholar
• Young JM, Bennett C, Gilhooly P, et al. Efficacy and safety of sildenafil citrate (Viagra®) in black and hispanic american men. Urology 2002;4295:39–48
   Google Scholar
• Glina S, Bertero E, Claro J, et al. Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. International journal of impotence research 2002;14:S27–32
   Google Scholar
• Choi HK, Ahn TY, Kim JJ, et al. A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. International journal of impotence research 2003;15:80–6
   Google Scholar
• Zonana Farca E, Francolugo-Vélez V, Moy-Eransus C, et al. Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res 2008;20:402–8
   Google Scholar
• Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001;57:960–5
   PubMed Web of Science ®Google Scholar
• Park HJ, Park NC, Shim HB, et al. An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008;5:2405–13
   Google Scholar
• Albuquerque DC, Miziara LJ, Saraiva JFK, et al. Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. Braz J Urol 2005;31:342–53; discussion 354–5
   Google Scholar
• Pickering TG, Shepherd AMM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004;17:1135–42
   PubMed Web of Science ®Google Scholar
• Aranda P. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004;17:139–45
   PubMed Web of Science ®Google Scholar
• Rubio-Aurioles E, Porst H, Eardley I, Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006;3:1037–49
   PubMed Web of Science ®Google Scholar
• Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005;95:36–42
   PubMed Web of Science ®Google Scholar
• Amin A, Mahmoudi E, Navid H, Chitsazan M. Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure? Congestive Heart Failure 2013;19:99–103
   Google Scholar
• Rendell MS. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. J Am Med Assoc 1999;281:421–6
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Journal of diabetes and its complications 2004;18:205–10
   PubMed Web of Science ®Google Scholar
• Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15:821–5
   PubMedGoogle Scholar
• Escobar-Jiménez F. Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction. Med Clin (Barc) 2002;119:121–4
   Google Scholar
• Ergin S, Gunduz B, Ugurlu H, et al. A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. Spinal Cord 2008;31:522–31
   Google Scholar
• Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 1999;46:15–21
   PubMed Web of Science ®Google Scholar
• Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998;51:1629–33
   PubMed Web of Science ®Google Scholar
• Maytom MC, Derry FA, et al. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999;37:110–6
   PubMed Web of Science ®Google Scholar
• Sánchez Ramos A, Vidal J, Jáuregui ML, et al. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001;39:637–43
   PubMed Web of Science ®Google Scholar
• Schmid DM, Schurch B, Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000;38:184–93
   PubMed Web of Science ®Google Scholar
• Vozmedianochicharro R, Solermartinez J, Moralesjimenez P, et al. Estudio prospectivo para valorar el impacto del sildenafilo 50 mg/día durante 28 días en pacientes con disfunción eréctil y sintomatología del tracto urinario inferior secundaria a hiperplasia benigna de próstata. Revista Internacional de Andrología 2008;6:84–8
   Google Scholar
• Moemen MN, Fahmy I, AbdelAal M, et al. Erectile dysfunction in spinal cord-injured men: different treatment options. Int J Impot Res 2008;20:181–7
   PubMed Web of Science ®Google Scholar
• Perimenis P, Karkoulias K, Konstantinopoulos A, et al. Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient’s satisfaction with treatment. Asian J Androl 2007;9:259–64
   Google Scholar
• Perimenis P, Konstantinopoulos A, Karkoulias K, et al. Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea. Int Urol Nephrol 2007;39:547–52
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009;181:252–8
   PubMedGoogle Scholar
• Fowler CJ. A double blind, randomised sutdy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Am Med Assoc 2005;76:700–5
   Google Scholar
• El-Bahnasawy MS, Ismail T, Elsobky E, et al. Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy. Scandinavian journal of urology and nephrology 2008;42:110–5
   PubMed Web of Science ®Google Scholar
• Weber DC, Bieri S, Kurtz JM, Miralbell R. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999;17:3444–9
   PubMedGoogle Scholar
• Fava M, Nurnberg HG, Seidman SN, et al. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry 2006;67:240–6
   PubMed Web of Science ®Google Scholar
• Dording CM, LaRocca RA, Hails KA, et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013;25:3–10
   Google Scholar
• Hussain IF. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371–4
   PubMed Web of Science ®Google Scholar
• Raffaele R. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol 2002;41:382–6
   PubMed Web of Science ®Google Scholar
• Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. Am JKidney Dis 2005;45:381–7
   Google Scholar
• Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003;18:411–7
   PubMedGoogle Scholar
• Seibel I. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002;13:2770–5
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Kolahi AA, Ghaedi G. Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. BJU International 2009;104:376–83
   PubMed Web of Science ®Google Scholar
• Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313–21
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabé A, De Bonis W, et al. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 2010;7:3763–42
   Google Scholar
• Fisher DG, Malow R, Rosenberg R, et al. Recreational viagra use and sexual risk among drug abusing men. Am J Infect Dis 2006;2:107–14
   PubMedGoogle Scholar
• DeBusk R. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147–53
   PubMed Web of Science ®Google Scholar